{"id":463,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"survodutide-glucagon-glp-1-research-status-and-material-identity","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","title":{"rendered":"Survodutide Forschungsstatus: Duales Glucagon\/GLP-1 Biologie, Studien und Materialidentit\u00e4t"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Survodutide ist ein dualer Glucagon-Rezeptor- und GLP-1-Rezeptor-Agonist in der klinischen Entwicklung. \u201eDualer Agonist\u201c beschreibt die Rezeptorpharmakologie; Es handelt sich nicht um eine Bescheinigung \u00fcber den klinischen Status oder um den Nachweis, dass zwei Materialien mit derselben Kurzbezeichnung gleichwertig sind.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Was die Aufzeichnung zeigt<\/h2><ul class=\"wp-block-list\"><li>Die Ergebnisse der Phase 2 und der Phase 3 m\u00fcssen der untersuchten Formulierung und Population zugeordnet werden.<\/li><li>Das 2026-Phasenpapier 3 beschreibt Survodutid immer noch als Pr\u00fcfpr\u00e4parat.<\/li><li>Sequenz-, Gegenion-, Reinheits-, Gehalts- und Verunreinigungskontrollen bleiben chargenspezifische Fragen.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png\" alt=\"Wissenschaftler \u00fcberpr\u00fcft Daten aus Stoffwechselstudien und zwei Rezeptorsignalwege\" class=\"wp-image-457\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Originale redaktionelle Illustration zur Identifizierung des Forschungsthemas. Es stellt keine Katalogcharge, kein zugelassenes Medikament, kein Testergebnis oder keine klinische Verwendung dar.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Die Identit\u00e4ts- und Beweisgrenze<\/h2><p class=\"wp-block-paragraph\">Das Phase-2-Programm stellte ein Dosisfindungssignal her, w\u00e4hrend SYNCHRONIZE-1 das erste ver\u00f6ffentlichte Phase-3-Ergebnis zur Adipositas lieferte. Diese Aufzeichnungen beantworten Fragen zur klinischen Entwicklung. Sie beantworten nicht, ob eine Katalogcharge die gleiche Reihenfolge, Rezeptur, das gleiche Expositionsprofil oder die gleichen Herstellungskontrollen aufweist.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Rezeptorprofil<\/strong><span>Glucagonrezeptor + GLP-1-Rezeptoragonismus<\/span><\/div><div class=\"pim-evidence-row\"><strong>Aktueller Beweisanker<\/strong><span>SYNCHRONIZE-1, NCT06066515<\/span><\/div><div class=\"pim-evidence-row\"><strong>Kataloggrenze<\/strong><span>Kein R\u00fcckschluss auf die \u00c4quivalenz von Versuchsformulierung<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Was in die Materialakte geh\u00f6rt<\/h2><p class=\"wp-block-paragraph\">Notieren Sie bei Forschungsauftr\u00e4gen die genaue Sequenz und molekulare Form, den Peptidgehalt, die chromatographische Methode, die Massenbest\u00e4tigung, Informationen zu Wasser und Gegenionen sowie etwaige Aggregations- oder Verunreinigungsanforderungen. Vermeiden Sie es, ein Forschungsmaterial als klinische Intervention ohne dokumentarische Verkn\u00fcpfung zu beschreiben.<\/p><h2 class=\"wp-block-heading\">Redaktionelle Regel<\/h2><p class=\"wp-block-paragraph\">Verwenden Sie den genauen Interventionsnamen, das Modell, die Population und den Endpunkt aus dem zitierten Datensatz. Wandeln Sie eine Assoziation, einen Mechanismus, ein Tierergebnis, eine genehmigte Fertigarzneimittelaufzeichnung oder einen analytischen Test nicht in einen Anspruch \u00fcber eine nicht verwandte Katalogcharge um.<\/p>","protected":false},"excerpt":{"rendered":"<p>Survodutide ist ein dualer Glucagon-Rezeptor- und GLP-1-Rezeptor-Agonist in der klinischen Entwicklung. \u201eDualer Agonist\u201c beschreibt die Rezeptorpharmakologie; Es handelt sich nicht um eine Bescheinigung \u00fcber den klinischen Status oder um den Nachweis, dass zwei Materialien mit derselben Kurzbezeichnung gleichwertig sind.<\/p>","protected":false},"author":1,"featured_media":628,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"365","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"Phase 2 and phase 3 records; development and identity review","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Survodutide Once Weekly for Adults with Obesity \u2014 SYNCHRONIZE-1\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42253238\/\",\"note\":\"2026 phase 3 primary record; PMID 42253238.\"},{\"title\":\"Survodutide phase 2 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38330987\/\",\"note\":\"Dose-ranging clinical context; PMID 38330987.\"},{\"title\":\"ClinicalTrials.gov NCT06066515\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT06066515\",\"note\":\"Registry record for SYNCHRONIZE-1.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Survodutide Research Status: Trials &amp; Material Identity<\/title>\n<meta name=\"description\" content=\"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/survodutide-glucagon-glp-1-research-status-and-material-identity\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity\" \/>\n<meta property=\"og:description\" content=\"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/survodutide-glucagon-glp-1-research-status-and-material-identity\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Survodutide Research Status: Dual Glucagon\\\/GLP-1 Biology, Trials and Material Identity\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"articleSection\":[\"Evidence &amp; Quality Guides\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\",\"name\":\"Survodutide Research Status: Trials & Material Identity\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Survodutide Research Status: Dual Glucagon\\\/GLP-1 Biology, Trials and Material Identity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Survodutide Forschungsstatus: Studien und Materialidentit\u00e4t","description":"Survodutide ist ein dualer Glucagon-Rezeptor- und GLP-1-Rezeptor-Agonist in der klinischen Entwicklung. \u201eDualer Agonist\u201c beschreibt die Rezeptorpharmakologie; es ist kein cer\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","og_locale":"de_DE","og_type":"article","og_title":"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity","og_description":"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026","og_url":"https:\/\/nhdbio.com\/de\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","articleSection":["Evidence &amp; Quality Guides"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","url":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","name":"Survodutide Forschungsstatus: Studien und Materialidentit\u00e4t","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Survodutide ist ein dualer Glucagon-Rezeptor- und GLP-1-Rezeptor-Agonist in der klinischen Entwicklung. \u201eDualer Agonist\u201c beschreibt die Rezeptorpharmakologie; es ist kein cer\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=463"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/463\/revisions"}],"predecessor-version":[{"id":513,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/463\/revisions\/513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/628"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}